202 related articles for article (PubMed ID: 17005632)
1. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Schadendorf D; Hauschild A; Ugurel S; Thoelke A; Egberts F; Kreissig M; Linse R; Trefzer U; Vogt T; Tilgen W; Mohr P; Garbe C
Ann Oncol; 2006 Oct; 17(10):1592-7. PubMed ID: 17005632
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Agarwala SS; Kirkwood JM; Gore M; Dreno B; Thatcher N; Czarnetski B; Atkins M; Buzaid A; Skarlos D; Rankin EM
J Clin Oncol; 2004 Jun; 22(11):2101-7. PubMed ID: 15169796
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Lewis KD; Gibbs P; O'Day S; Richards J; Weber J; Anderson C; Zeng C; Baron A; Russ P; Gonzalez R
Cancer Invest; 2005; 23(4):303-8. PubMed ID: 16100942
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Hofmann M; Kiecker F; Wurm R; Schlenger L; Budach V; Sterry W; Trefzer U
J Neurooncol; 2006 Jan; 76(1):59-64. PubMed ID: 16132502
[TBL] [Abstract][Full Text] [Related]
5. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Hwu WJ; Lis E; Menell JH; Panageas KS; Lamb LA; Merrell J; Williams LJ; Krown SE; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2005 Jun; 103(12):2590-7. PubMed ID: 15861414
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D
Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Larkin JM; Hughes SA; Beirne DA; Patel PM; Gibbens IM; Bate SC; Thomas K; Eisen TG; Gore ME
Br J Cancer; 2007 Jan; 96(1):44-8. PubMed ID: 17146474
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Bafaloukos D; Gogas H; Georgoulias V; Briassoulis E; Fountzilas G; Samantas E; Kalofonos Ch; Skarlos D; Karabelis A; Kosmidis P
J Clin Oncol; 2002 Jan; 20(2):420-5. PubMed ID: 11786569
[TBL] [Abstract][Full Text] [Related]
10. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Siena S; Crinò L; Danova M; Del Prete S; Cascinu S; Salvagni S; Schiavetto I; Vitali M; Bajetta E
Ann Oncol; 2010 Mar; 21(3):655-661. PubMed ID: 19767314
[TBL] [Abstract][Full Text] [Related]
11. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
Bafaloukos D; Tsoutsos D; Fountzilas G; Linardou H; Christodoulou C; Kalofonos HP; Briassoulis E; Panagiotou P; Hatzichristou H; Gogas H
Melanoma Res; 2004 Aug; 14(4):289-94. PubMed ID: 15305160
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D
Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660
[TBL] [Abstract][Full Text] [Related]
13. [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Frick S; Lischner S; Rosien F; Haacke TC; Schäfer F; Christophers E; Hauschild A
Hautarzt; 2002 Oct; 53(10):659-65. PubMed ID: 12297947
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
McQuade JL; Posada LP; Lecagoonporn S; Cain S; Bassett RL; Patel SP; Hwu WJ; Hwu P; Davies MA; Bedikian AY; Amaria RN
Melanoma Res; 2016 Dec; 26(6):604-608. PubMed ID: 27540836
[TBL] [Abstract][Full Text] [Related]
16. The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
Guida M; Tommasi S; Strippoli S; Natalicchio MI; De Summa S; Pinto R; Cramarossa A; Albano A; Pisconti S; Aieta M; Ridolfi R; Azzariti A; Guida G; Lorusso V; Colucci G
BMC Cancer; 2018 May; 18(1):552. PubMed ID: 29747595
[TBL] [Abstract][Full Text] [Related]
17. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Patel PM; Suciu S; Mortier L; Kruit WH; Robert C; Schadendorf D; Trefzer U; Punt CJ; Dummer R; Davidson N; Becker J; Conry R; Thompson JA; Hwu WJ; Engelen K; Agarwala SS; Keilholz U; Eggermont AM; Spatz A;
Eur J Cancer; 2011 Jul; 47(10):1476-83. PubMed ID: 21600759
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Chiarion-Sileni V; Guida M; Ridolfi L; Romanini A; Del Bianco P; Pigozzo J; Brugnara S; Colucci G; Ridolfi R; De Salvo GL;
Br J Cancer; 2011 Jun; 104(12):1816-21. PubMed ID: 21610711
[TBL] [Abstract][Full Text] [Related]
19. Metastatic melanoma: a regional review and future directions.
Khan KH; Goody RB; Hameed H; Jalil A; Coyle VM; McAleer JJ
Tumori; 2012; 98(5):575-80. PubMed ID: 23235751
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Bael TE; Peterson BL; Gollob JA
Melanoma Res; 2008 Apr; 18(2):147-51. PubMed ID: 18337652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
